FC2 female condom recommended for approval
A team of cancer researchers from several Boston academic medical centers has discovered a potential treatment for a group of tumors that have resisted previous targeted therapy approaches. In their Nature Medicine report, which is receiving early online release, investigators from Dana-Farber Cancer Institute (DFCI), Massachusetts General Hospital (MGH) Cancer Center, and Beth Israel Deaconess
Full Post: Advance in K-Ras-mutated cancer research
The Female Health Company has announced that the U.S. Food and Drug Administration’s (FDA) Obstetrics and Gynecology Devices Advisory Committee has unanimously voted that the company’s second-generation female condom, the FC2 Female Condom, is approvable with a single condition.
The Advisory Committee voted 15-0 that the product is approvable with the condition that the FC2 Female Condom’s instructions for use continue to follow use instructions for the FC Female Condom(R) (FC1 Female Condom) and appropriately identify the study that was performed to establish the comparable safety and effectiveness of FC2 with FC1.
The FDA is not bound by the committee’s recommendation, but it takes its advice into consideration when reviewing obstetric and gynecologic devices.
“We are very pleased with today’s outcome and look forward to working with the FDA as it continues to review our application for the FC2 Female Condom,” said Dr. Mary Ann Leeper, FHC’s Senior Strategic Advisor. “We believe that FHC’s second-generation female condom can strengthen the fight against AIDS by expanding affordable access to a woman-initiated HIV prevention method.”
The company filed the FC2 Female Condom Pre-market Approval Application (PMA) with the FDA on January 7, 2008 and has been working with FDA as it reviewed the application.
The company’s first-generation FC1 Female Condom received FDA approval for distribution in the United States in 1993. The FC1 Female Condom is also included in the World Health Organization’s (WHO) essential products list for distribution by United Nations (UN) agencies. Since its approval, 165 million FC1 Female Condoms have been distributed in 142 countries.
The FC2 Female Condom data has been reviewed by other public agencies, including the European Union, India, Brazil and the World Health Organization (WHO). In 2006, the WHO agreed that the FC2 Female Condom does perform in the same manner as the FC1 Female Condom and recommended that the FC2 Female Condom can be purchased by UN agencies. Since then, over 22 million FC2 female condoms have been distributed in 77 countries.
Performance of FC2 Female Condom in Clinical Trial
FHC presented data from a randomized, double-blind, crossover, comparative trial with the FC1 Female Condom. The FC1 Female Condom is currently distributed in over 100 countries, including the U.S. The FC2 Female Condom, which looks very similar to the FC1 Female Condom, was developed to expand access to women at risk of HIV and STIs by lowering the cost of the product through the introduction of a more efficient manufacturing process. The clinical trial was conducted in 2004 by the Reproductive Health and HIV Research Unit of the University of Witwatersrand in South Africa. Over 200 women participated in the study. The results of the study showed that the FC2 Female Condom is safe and that the risk of failure during use was equivalent to FC1. Results from the study were originally published in the journal Contraception. (See Contraception 73 (2006) 386- 393.)
Unintended Pregnancy and HIV/STI Transmission in the U.S.
Unintended pregnancy and the transmission of HIV and other STIs remain significant public health challenges in the U.S. According to the Centers for Disease Control and Prevention (CDC), approximately one-half of pregnancies in the U.S. were unintended in 2001, and contraception methods provided by federally funded family planning programs (male condoms, female condoms, the Pill, and IUDs) prevent an estimated 1.3 million unintended pregnancies each year.
Over the past two decades, the proportion of women among all people living with HIV/AIDS (PLHIV) in the U.S. has more than tripled — from 8 percent of PLHIV in 1985 to 26 percent in 2007. HIV infection has emerged as the leading cause of death for African American women aged 25-34, high-risk heterosexual contact is responsible for 80 percent of new HIV infections among American women, and one in four young adults aged 15-20 years contracts a sexually transmitted infection each year.
In this context, expanded access to the female condom — the only safe, effective, and available woman-initiated prevention method currently available — can provide women and men with more options to practice safer sex and prevent unintended pregnancy.
Sometimes the person struck in such problems which are very difficult to handle. If we see towards our world then it is also facing very problem. One of the known problems is the rise temperature due to global warming. In this article I shall concentrate the attention of people towards the population. The current world
Full Post: Want To Prevent Fertilization - Use Birth Control Methods
New data from The Kinsey Institute at Indiana University demonstrate that many women think condoms undermine sexual pleasure, but those who use both hormonal contraception and condoms report higher overall sexual satisfaction. The study authors suggest that this inconsistency reflects how women think about their contraceptive method when asked questions about two different aspects of
Full Post: Contraceptive methods and women’s sexuality
Less experienced prostitutes are more likely to have sexually transmitted infections (STIs). A study of more than a thousand female sex workers in Cambodia, reported in the open access journal BMC Infectious Diseases, has shown that girls who were new to the sex industry were twice as likely to have gonorrhoea or chlamydia. Heng Sopheab
Full Post: Inexperienced sex workers most at risk of sexual infections
A review of previously published studies suggests that rates of adverse outcomes for mothers or pregnant women and newborn babies, such as gestational diabetes and low birth weight, may be lower after bariatric surgery compared with pregnant women who are obese, according to an article in the November 19 issue of JAMA, the Journal of
Full Post: Risk of maternal and newborn complications may be lower after bariatric surgery
Exposure to folic acid antagonists during pregnancy is associated with a higher risk of placenta-mediated adverse outcomes such as preeclampsia, placental abruption, fetal growth restriction or fetal death reports a retrospective cohort study published in CMAJ (pdf). Folic acid antagonists include a broad range of drugs used to treat epilepsy, mood disorders, hypertension and infections.
Full Post: Exposure to folic acid antagonists during pregnancy has risks